COMMUNIQUÉS West-GlobeNewswire

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
07/05/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new [...]
SS Innovations Demonstrates Long-Distance Telesurgery Capabilities at Royal Australian College of Surgeons Annual Scientific Congress
07/05/2026
Landmark telesurgery performed in Perth, Australia, more than 4,500 miles from the patient in India, utilizing the SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console FORT LAUDERDALE, Fla., May 07 [...]
Prenetics’ IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
07/05/2026
IM8 products, including Daily Ultimate Essentials, Daily Ultimate Longevity, and The Beckham Stack, to be integrated into Inter Miami’s training facility and made available to all players NEW YORK and MIAMI, May 07, [...]
Reporting of transactions in NTG’s shares made by persons discharging managerial responsibilities and persons closely associated with them
07/05/2026
Company announcement no. 15 – 26 7 May 2026 Reporting of transactions in NTG’s shares made by persons discharging managerial responsibilities and persons closely associated with them In accordance with section 19 of [...]
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
07/05/2026
Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in heparin-induced thrombocytopenia (HIT) PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal [...]
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
07/05/2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it [...]
Tria Federal Unveils Integrated Solutions Platform and New Website
07/05/2026
Tria helps federal health agencies achieve their critical missions by navigating complex tradeoffs between cost, quality, and access to care ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Tria Federal has unveiled a [...]
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
07/05/2026
Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE [...]
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
07/05/2026
Renewed agreement provides streamlined access to ENvue equipment and supplies across a network of more than 90 hospitals in 17 states TYLER, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc . (NASDAQ: FEED) (“ [...]
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
07/05/2026
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved therapies [...]
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
07/05/2026
Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment Financing also drives early- and [...]
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
07/05/2026
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant [...]
MediWound to Report First Quarter 2026 Financial Results
07/05/2026
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global [...]
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
07/05/2026
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic [...]
Stryker declares an $0.88 per share quarterly dividend
07/05/2026
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the [...]
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
07/05/2026
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, [...]
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
07/05/2026
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental [...]
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
07/05/2026
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory [...]
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
07/05/2026
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the randomized ASPEN-06 [...]

Pages